F-598 is under clinical development by Alopexx and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect F-598’s likelihood of approval (LoA) and phase transition for Hospital-Acquired Infections took place on 04 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their F-598 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

F-598 overview

F598 (SAR-279356) is under development for the treatment of poly-N-acetylglucosamine (PNAG) infections, S. pneumoniae-induced Pneumonia, gram-negative bacterial infections, hospital-acquired infections, gram-positive bacterial infections, fungal infections, pulmonary tuberculosis and for the prevention of infection after emergency abdominal surgery or abdominal trauma. The therapeutic candidate binds to a conserved surface polysaccharide known as poly-N-acetyl glucosamine (PNAG). F598 is a fully human monoclonal antibody. The drug is administered through intravenous infusion. It was under development for prevention and treatment of serious bacterial infections like gonorrhea in intensive care unit (ICU) patients on mechanical ventilation.

Alopexx overview

Alopexx is a clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics. Alopexx is headquartered in Cambridge, Massachusetts, the US.

Quick View F-598 LOA Data

Report Segments
  • Innovator
Drug Name
  • F-598
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Alopexx
  • Originator: Harvard Medical School
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.